Home>>Signaling Pathways>> GPCR/G protein>> Adenosine Receptor>>A2AR-agonist-1

A2AR-agonist-1 (Synonyms: JMF 1907)

Catalog No.GC30987

An agonist of adenosine A2A receptor and inhibitor of ENT1

Products are for research use only. Not for human use. We do not sell to patients.

A2AR-agonist-1 Chemical Structure

Cas No.: 41552-95-8

Size Price Stock Qty
10mM (in 1mL DMSO)
$354.00
In stock
5mg
$321.00
In stock
10mg
$459.00
In stock
50mg
$1,379.00
In stock
100mg
$1,930.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

A2AR-agonist-1 is a potent A2AR and ENT1 agonist with Ki of 4.39 and 3.47 for A2AR and ENT1.IC50 value: 4.39 and 3.47 (Ki) [1]Target: A2AR and ENT1A2AR-agonist-1 is a novel dual-action compound, targeting the Adenosine A2A Receptor and Adenosine Transporter for Neuroprotection.[1]

[1]. Chen JB, et al. Design and synthesis of novel dual-action compounds targeting the adenosine A(2A) receptor and adenosine transporter for neuroprotection. ChemMedChem. 2011 Aug 1;6(8):1390-1400. [2]. Lin Yun-Lian, et al. Dual-action compounds targeting adenosine A2A receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases. From PCT Int. Appl. (2012), WO 2012064340 A1 20120518. [3]. Chen, Chih-Cheng, et al. Methods and compositions for treating pain. From PCT Int. Appl. (2013), WO 2013120078 A1 20130815.

Reviews

Review for A2AR-agonist-1

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for A2AR-agonist-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.